DZ Bank
CRSP icon

DZ Bank’s CRISPR Therapeutics CRSP Stock Holding History

DZ Bank’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-460
Closed -$21.6K – 963
2024
Q3 		$21.6K Buy
+460
New +$23.3K ﹤0.01% 953
2022
Q1 		– Sell
-367,116
Closed -$28.9M – 1009
2021
Q4 		$28.9M Buy
367,116
+183,558
+100% +$16M 0.02% 312
2021
Q3 		$20.5M Hold
183,558
– – 0.03% 279
2021
Q2 		$29.7M Hold
183,558
– – 0.05% 225
2021
Q1 		$22.4M Buy
+183,558
New +$27.7M 0.04% 241

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DZ Bank's CRSP Position: Q4 2024 in Review

DZ Bank sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 460 shares — an estimated $21.6K sold.

DZ Bank first reported a position in CRSP in Q1 2021 and held it in 5 quarters. The position peaked at $29.7M in Q2 2021. 405 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

  • DZ Bank reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
  • DZ Bank sold 460 CRISPR Therapeutics shares in Q4 2024, an estimated $21.6K.
  • DZ Bank first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 5 quarters.
  • DZ Bank's CRISPR Therapeutics position peaked at $29.7M in Q2 2021.
  • 405 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on DZ Bank's 13F filing for Q4 2024, filed 14 Feb 2025.